Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 776

1.

Serum free light chain measurements to reduce 24-hour urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein.

Tschautscher M, Rajkumar V, Dispenzieri A, Lacy M, Gertz M, Buadi F, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman S, Zeldenrust S, Lust J, Russell S, Leung N, Kapoor P, Go R, Lin Y, Gonsalves W, Kourelis T, Warsame R, Kyle R, Kumar S.

Am J Hematol. 2018 Jul 17. doi: 10.1002/ajh.25215. [Epub ahead of print]

PMID:
30016549
2.

Clinical characteristics and treatment outcomes in IgE multiple myeloma: A case-control study.

Jurczyszyn A, Castillo JJ, Vesole DH, Liu J, Avivi I, Waszczuk-Gajda A, Lech-Maranda E, Gentile M, Mikala G, Guerrero-Garcia T, Suska A, Gertz MA.

Am J Hematol. 2018 Jul 10. doi: 10.1002/ajh.25209. [Epub ahead of print] No abstract available.

PMID:
29989240
3.

Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement.

Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, Dispenzieri A, Fonseca R, Hayman SR, Kapoor P, Kourelis TV, Lacy MQ, Larsen JT, Muchtar E, Reeder CB, Sher T, Stewart AK, Warsame R, Go RS, Kyle RA, Leung N, Lin Y, Lust JA, Russell SJ, Zeldenrust SR, Fonder AL, Hwa YL, Hobbs MA, Mayo AA, Hogan WJ, Rajkumar SV, Kumar SK, Gertz MA, Roy V.

Bone Marrow Transplant. 2018 Jul 9. doi: 10.1038/s41409-018-0264-8. [Epub ahead of print] Review.

PMID:
29988062
4.

Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.

Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Planté-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceição I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T.

N Engl J Med. 2018 Jul 5;379(1):22-31. doi: 10.1056/NEJMoa1716793.

PMID:
29972757
5.

Prognostic significance of stringent complete response post stem cell transplantation in AL amyloidosis.

Sidiqi MH, Aljama M, Jevremovic D, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Gonsalves WI, Kumar S, Kapoor P, Kourelis T, Leung N, Hogan WJ, Gertz M.

Biol Blood Marrow Transplant. 2018 Jun 29. pii: S1083-8791(18)30366-5. doi: 10.1016/j.bbmt.2018.06.027. [Epub ahead of print]

PMID:
29964192
6.

Autologous stem cell transplant for AL amyloidosis patients aged 70 to 75.

Sidiqi MH, Aljama MA, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Kumar SK, Gertz MA.

Biol Blood Marrow Transplant. 2018 Jun 19. pii: S1083-8791(18)30329-X. doi: 10.1016/j.bbmt.2018.06.017. [Epub ahead of print]

PMID:
29933071
7.

Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.

Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK.

Blood Cancer J. 2018 Jun 12;8(6):59. doi: 10.1038/s41408-018-0077-4.

8.

Defining Lymphoplasmacytic Lymphoma: Does MYD88L265P Define a Pathologically Distinct Entity Among Patients With an IgM Paraprotein and Bone Marrow-Based Low-Grade B-Cell Lymphomas With Plasmacytic Differentiation?

Fang H, Kapoor P, Gonsalves WI, Frederick LA, Viswanatha D, Howard MT, He R, Morice WG 2nd, McPhail ED, Greipp PT, Ansell SM, Kyle RA, Gertz MA, Paludo J, Abeykoon J, King RL.

Am J Clin Pathol. 2018 Jul 3;150(2):168-176. doi: 10.1093/ajcp/aqy041.

PMID:
29868855
9.

Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders.

Higgins L, Nasr SH, Said SM, Kapoor P, Dingli D, King RL, Rajkumar SV, Kyle RA, Kourelis T, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Ansell SM, Gonsalves WI, Thompson CA, Fervenza FC, Zand L, Hwa YL, Jevremovic D, Shi M, Leung N.

Clin J Am Soc Nephrol. 2018 Jul 6;13(7):1037-1046. doi: 10.2215/CJN.13041117. Epub 2018 May 30.

PMID:
29848505
10.

Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018.

Gertz MA.

Blood Cancer J. 2018 May 23;8(5):44. doi: 10.1038/s41408-018-0080-9. Review.

11.

Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis.

Milani P, Dispenzieri A, Scott CG, Gertz MA, Perlini S, Mussinelli R, Lacy MQ, Buadi FK, Kumar S, Maurer MS, Merlini G, Hayman SR, Leung N, Dingli D, Klarich KW, Lust JA, Lin Y, Kapoor P, Go RS, Pellikka PA, Hwa YL, Zeldenrust SR, Kyle RA, Rajkumar SV, Grogan M.

Circ Cardiovasc Imaging. 2018 May;11(5):e006588. doi: 10.1161/CIRCIMAGING.117.006588.

PMID:
29752392
12.

Waldenström macroglobulinemia treatment algorithm 2018.

Gertz MA.

Blood Cancer J. 2018 May 1;8(4):40. doi: 10.1038/s41408-018-0076-5. Review.

13.

Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation.

Chakraborty R, Muchtar E, Kumar SK, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Warsame R, Kourelis T, Gonsalves W, Gertz MA.

Br J Haematol. 2018 Jul;182(1):71-77. doi: 10.1111/bjh.15244. Epub 2018 Apr 29.

PMID:
29707759
14.

Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation.

Sidiqi MH, Aljama MA, Jevremovic D, Morice WG, Timm M, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Gonsalves WI, Kumar S, Kapoor P, Kourelis T, Leung N, Hogan WJ, Gertz M.

Haematologica. 2018 Jul;103(7):1229-1234. doi: 10.3324/haematol.2018.189985. Epub 2018 Apr 19.

15.

Time to plateau as a predictor of survival in newly diagnosed multiple myeloma.

Mellors PW, Binder M, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa YL, Fonder A, Hobbs M, Kourelis T, Warsame R, Zeldenrust SR, Lust JA, Leung N, Go RS, Kyle RA, Vincent Rajkumar S, Kumar SK.

Am J Hematol. 2018 Jul;93(7):889-894. doi: 10.1002/ajh.25113.

PMID:
29659048
16.

Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma.

Kansagra A, Gonsalves WI, Gertz MA, Buadi FK, Dingli D, Dispenzieri A, Lacy MQ, Hayman SR, Kapoor P, Muchtar E, Kourelis TV, Warsame R, Leung N, Zeldenrust SR, Lust JA, Rajkumar SV, Kyle RA, Hogan W, Kumar SK.

Biol Blood Marrow Transplant. 2018 Apr 12. pii: S1083-8791(18)30188-5. doi: 10.1016/j.bbmt.2018.04.007. [Epub ahead of print]

PMID:
29656139
17.

Multiple myeloma - a cure within reach.

Gertz MA.

Leuk Lymphoma. 2018 Apr 4:1-3. doi: 10.1080/10428194.2018.1452221. [Epub ahead of print] No abstract available.

PMID:
29616849
18.

Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.

Sidiqi MH, Aljama MA, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Leung N, Gonsalves WI, Kumar SK, Kapoor P, Kourelis TV, Hogan WJ, Gertz MA.

Blood Adv. 2018 Apr 10;2(7):769-776. doi: 10.1182/bloodadvances.2018016782.

19.

Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.

Paludo J, Abeykoon JP, Shreders A, Ansell SM, Kumar S, Ailawadhi S, King RL, Koehler AB, Reeder CB, Buadi FK, Dispenzieri A, Lacy MQ, Dingli D, Witzig TE, Go RS, Gonsalves WI, Kourelis T, Warsame R, Leung N, Habermann TM, Hayman S, Lin Y, Kyle RA, Rajkumar SV, Gertz MA, Kapoor P.

Ann Hematol. 2018 Aug;97(8):1417-1425. doi: 10.1007/s00277-018-3311-z. Epub 2018 Apr 3.

PMID:
29610969
20.

Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria.

Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Grogan M, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Chakraborty R, Gonsalves W, Kourelis TV, Warsame R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA.

Leukemia. 2018 Feb 20. doi: 10.1038/s41375-018-0060-x. [Epub ahead of print]

PMID:
29581546
21.

Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance.

Lakshman A, Paul S, Rajkumar SV, Ketterling RP, Greipp PT, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK.

Leukemia. 2018 Jan 30. doi: 10.1038/s41375-018-0030-3. [Epub ahead of print] No abstract available.

PMID:
29568092
22.

The importance of bone marrow examination in patients with light chain amyloidosis achieving a complete response.

Sidana S, Tandon N, Dispenzieri A, Gertz MA, Rajkumar SV, Kumar SK.

Leukemia. 2018 May;32(5):1243-1246. doi: 10.1038/s41375-018-0022-3. Epub 2018 Jan 30. No abstract available.

PMID:
29568089
23.

Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time.

Sidiqi MH, Aljama MA, Buadi FK, Warsame RM, Lacy MQ, Dispenzieri A, Dingli D, Gonsalves WI, Kumar S, Kapoor P, Kourelis T, Hogan WJ, Gertz MA.

J Clin Oncol. 2018 May 1;36(13):1323-1329. doi: 10.1200/JCO.2017.76.9554. Epub 2018 Mar 20.

PMID:
29558277
24.

Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?

Muchtar E, Gertz MA, Kumar SK, Lin G, Boilson B, Clavell A, Lacy MQ, Buadi FK, Hayman SR, Kapoor P, Dingli D, Rajkumar SV, Dispenzieri A, Grogan M.

Amyloid. 2018 Mar 12:1-7. doi: 10.1080/13506129.2018.1449744. [Epub ahead of print]

PMID:
29529877
25.

Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis.

Sidana S, Tandon N, Dispenzieri A, Gertz MA, Dingli D, Jevremovic D, Morice WG, Kapoor P, Kourelis TV, Lacy MQ, Hayman SR, Buadi FK, Leung N, Go RS, Lin Y, Russell SJ, Lust JA, Zeldenrust SR, Warsame R, Hwa YL, Hobbs M, Fonder A, Kyle RA, Rajkumar SV, Kumar SK, Gonsalves WI.

Leukemia. 2018 Jun;32(6):1421-1426. doi: 10.1038/s41375-018-0063-7. Epub 2018 Feb 21.

PMID:
29483709
26.

Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia-Reply.

Kapoor P, Gertz MA, Ansell SM.

JAMA Oncol. 2018 May 1;4(5):745-746. doi: 10.1001/jamaoncol.2017.5100. No abstract available.

PMID:
29392293
27.

Testicular plasmacytoma: unique location or circumstantial presentation?

Muchtar E, Bladé J, Gertz MA.

Leuk Lymphoma. 2018 Aug;59(8):1769-1771. doi: 10.1080/10428194.2017.1421763. Epub 2018 Jan 9. No abstract available.

PMID:
29316841
28.

Reply to Castillo et al.

Abeykoon JP, King R, Ansell SM, Rajkumar SV, Paludo J, Kyle RA, Kumar S, Gertz MA, Kapoor P.

Am J Hematol. 2018 Mar;93(3):E71-E73. doi: 10.1002/ajh.25029. Epub 2018 Feb 5. No abstract available.

PMID:
29314230
29.

Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma.

Gertz MA, Buadi FK, Hayman SR, Lacy MQ, Dispenzieri A, Dingli D, Gonsalves WI, Kumar S, Kapoor P, Kourelis T, Hogan WJ.

Mayo Clin Proc. 2018 Jan;93(1):56-58. doi: 10.1016/j.mayocp.2017.09.012.

PMID:
29304921
30.

Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis.

Sidana S, Tandon N, Gertz MA, Dispenzieri A, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Lust JA, Russell SJ, Zeldenrust SR, Rajkumar SV, Hogan WJ, Kumar SK.

Bone Marrow Transplant. 2018 Mar;53(3):326-333. doi: 10.1038/s41409-017-0020-5. Epub 2017 Dec 21.

PMID:
29269795
31.

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X, Anderson KC.

Leukemia. 2018 Feb;32(2):252-262. doi: 10.1038/leu.2017.329. Epub 2017 Nov 16. Review.

32.

Reply.

Reynolds MM, Veverka KK, Gertz MA, Dispenzieri A, Zeldenrust SR, Leung N, Pulido JS.

Am J Ophthalmol. 2018 Feb;186:170. doi: 10.1016/j.ajo.2017.11.005. Epub 2017 Dec 13. No abstract available.

PMID:
29248199
33.

Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development.

Cleary Y, Gertz M, Morcos PN, Yu L, Youdim K, Phipps A, Fowler S, Parrott N.

Clin Pharmacol Ther. 2017 Dec 11. doi: 10.1002/cpt.956. [Epub ahead of print]

PMID:
29226313
34.

Outcomes of Patients With Familial Transthyretin Amyloidosis After Liver Transplantation.

Banerjee D, Roeker LE, Grogan M, Swiecicki P, Poterucha J, Heimbach J, Zeldenrust S, Gertz M, Edwards B, Daly R, Klarich KW, Dispenzieri A.

Prog Transplant. 2017 Sep;27(3):246-250. doi: 10.1177/1526924817715463. Epub 2017 Jul 4.

PMID:
29187090
35.

Importance of FISH genetics in light chain amyloidosis.

Gertz MA, Dispenzieri A, Muchtar E.

Oncotarget. 2017 Sep 19;8(47):81735-81736. doi: 10.18632/oncotarget.21052. eCollection 2017 Oct 10. No abstract available.

36.

Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation.

Chakraborty R, Muchtar E, Kumar SK, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Gertz MA.

Bone Marrow Transplant. 2018 Feb;53(2):155-161. doi: 10.1038/bmt.2017.228. Epub 2017 Nov 13.

PMID:
29131152
37.

MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia.

Abeykoon JP, Paludo J, King RL, Ansell SM, Gertz MA, LaPlant BR, Halvorson AE, Gonsalves WI, Dingli D, Fang H, Rajkumar SV, Lacy MQ, He R, Kourelis T, Reeder CB, Novak AJ, McPhail ED, Viswanatha DS, Witzig TE, Go RS, Habermann TM, Buadi FK, Dispenzieri A, Leung N, Lin Y, Thompson CA, Hayman SR, Kyle RA, Kumar SK, Kapoor P.

Am J Hematol. 2018 Feb;93(2):187-194. doi: 10.1002/ajh.24955. Epub 2017 Nov 17.

PMID:
29080258
38.

OCULAR MANIFESTATIONS OF SYSTEMIC AMYLOIDOSIS.

Reynolds MM, Veverka KK, Gertz MA, Dispenzieri A, Zeldenrust SR, Leung N, Pulido JS.

Retina. 2018 Jul;38(7):1371-1376. doi: 10.1097/IAE.0000000000001901.

PMID:
29068915
39.

Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma.

Lakshman A, Singh PP, Rajkumar SV, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Dingli D, Hwa YL, Fonder AL, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Kumar SK.

Am J Hematol. 2018 Feb;93(2):179-186. doi: 10.1002/ajh.24954. Epub 2017 Nov 10.

PMID:
29067723
40.

Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges.

Gertz MA.

Am J Manag Care. 2017 Jun;23(7 Suppl):S107-S112. Review.

41.

Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL).

Tandon N, Sidana S, Dispenzieri A, Gertz MA, Lacy MQ, Dingli D, Buadi FK, Fonder AL, Hayman SR, Hwa YL, Hobbs MA, Kapoor P, Gonsalves WI, Leung N, Go RS, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Kumar SK.

Am J Hematol. 2018 Jan;93(1):17-22. doi: 10.1002/ajh.24919. Epub 2017 Oct 20.

PMID:
28960427
42.

External beam radiation therapy for amyloidosis of the urinary bladder.

Cooper CT, Greene BD, Fegan JE, Rovira D, Gertz MA, Marcus DM.

Pract Radiat Oncol. 2018 Jan - Feb;8(1):25-27. doi: 10.1016/j.prro.2017.08.003. Epub 2017 Aug 16. No abstract available.

PMID:
28958583
43.

Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.

Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Lust JA, Russell SJ, Zeldenrust SR, Rajkumar SV, Kumar SK.

Leukemia. 2018 Mar;32(3):729-735. doi: 10.1038/leu.2017.286. Epub 2017 Sep 18.

PMID:
28919633
44.

Restrictive Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy.

Muchtar E, Blauwet LA, Gertz MA.

Circ Res. 2017 Sep 15;121(7):819-837. doi: 10.1161/CIRCRESAHA.117.310982. Review.

PMID:
28912185
45.

Ocular Manifestations of Familial Transthyretin Amyloidosis.

Reynolds MM, Veverka KK, Gertz MA, Dispenzieri A, Zeldenrust SR, Leung N, Pulido JS.

Am J Ophthalmol. 2017 Nov;183:156-162. doi: 10.1016/j.ajo.2017.09.001. Epub 2017 Sep 11.

PMID:
28911993
46.

A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma.

Dispenzieri A, D'Souza A, Gertz MA, Laumann K, Wiseman G, Lacy MQ, LaPlant B, Buadi F, Hayman SR, Kumar SK, Dingli D, Hogan WJ, Ansell SM, Gastineau DA, Inwards DJ, Micallef IN, Porrata LF, Johnston PB, Litzow MR, Witzig TE.

Bone Marrow Transplant. 2017 Oct;52(10):1372-1377. doi: 10.1038/bmt.2017.164. Epub 2017 Sep 4.

PMID:
28869617
47.

Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma.

Binder M, Rajkumar SV, Ketterling RP, Greipp PT, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kyle RA, Kumar SK.

Blood Cancer J. 2017 Sep 1;7(9):e600. doi: 10.1038/bcj.2017.83.

48.

Unravelling hypothyroidism in AL amyloidosis: Authors' reply.

Muchtar E, Gertz MA.

J Intern Med. 2018 Jan;283(1):108. doi: 10.1111/joim.12681. Epub 2017 Sep 21. No abstract available.

PMID:
28861923
49.

Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial.

Ailawadhi S, Mikhael JR, LaPlant BR, Laumann KM, Kumar S, Roy V, Dingli D, Bergsagel PL, Buadi FK, Rajkumar SV, Fonseca R, Gertz MA, Kapoor P, Sher T, Hayman SR, Stewart AK, Dispenzieri A, Kyle RA, Gonsalves WI, Reeder CB, Lin Y, Go RS, Leung N, Kourelis T, Lust JA, Russell SJ, Chanan-Khan AA, Lacy MQ.

Leukemia. 2018 Mar;32(3):719-728. doi: 10.1038/leu.2017.258. Epub 2017 Sep 1.

PMID:
28860655
50.

Attitudes about when and how to treat patients with AL amyloidosis: an international survey.

Milani P, Gertz MA, Merlini G, Dispenzieri A.

Amyloid. 2017 Dec;24(4):213-216. doi: 10.1080/13506129.2017.1370421. Epub 2017 Aug 31.

PMID:
28857614

Supplemental Content

Support Center